New implant could replace monthly shots for opioid addiction

NCT ID NCT07064564

Recruiting now Disease control Sponsor: Akyso Therapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage trial tests a new naltrexone implant (iSTEP-N) that slowly releases medication over 12 months to block opioids. It will enroll 33 healthy adults and compare two implant doses to standard monthly injections. The goal is to see if the implant can maintain steady drug levels and be a more convenient treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: naltrexone implant
What this could lead to: If successful, this implant could provide a more convenient, long-lasting treatment option for opioid use disorder, reducing the need for monthly injections.
What could go wrong: This is an early Phase 1 study with only 33 healthy volunteers, so it may not show the expected drug levels or safety profile. The implant might not work as well as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

JBR Cenexel
RECRUITING

Millcreek, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.